
Sign up to save your podcasts
Or
Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
4.8
2626 ratings
Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
135 Listeners
111 Listeners
26,356 Listeners
27 Listeners
182 Listeners
2 Listeners
348 Listeners
56 Listeners
366 Listeners
136 Listeners
8 Listeners
29 Listeners
181 Listeners
48 Listeners
40 Listeners